Although it is known that, in the uterus, estrogen receptor ␣ (ER␣) is involved in proliferation and progesterone receptor in differentiation, the role of the two other gonadal-hormone receptors expressed in the uterus, androgen receptor (AR) and estrogen receptor ␤ (ER␤), remains undefined. In this study, the involvement of AR in 17␤-estradiol (E 2 )-induced cellular proliferation in the immature rat uterus was investigated. AR levels were low in the untreated immature uterus, but 24 h after treatment of rats with E 2 , there was an increase in the levels of AR and of two androgen-regulated genes, IGF-I and Crisp (cysteinerich secretory protein). As expected, E 2 induced proliferation of luminal epithelial cells. These actions of E 2 were all blocked by both the antiestrogen tamoxifen and the antiandrogen flutamide. The E 2 -induced AR was found by immunohistochemistry to be localized exclusively in the stroma, mainly in the myometrium, where it colocalized with ER␣ but not with ER␤. ER␤, detected with two different ER␤-specific antibodies, was expressed in both stromal and epithelial cells either alone or together with ER␣. Treatment with E 2 caused down-regulation of ER␣ and ER␤ in the epithelium. The data suggest that, in E 2 -induced epithelial cell proliferation, ER␣ induces stromal AR and AR amplifies the ER␣ signal by induction of IGF-I. Because AR is never expressed in cells with ER␤, it is unlikely that ER␤ signaling is involved in this pathway. These results indicate an important role for AR in proliferation of the uterus, where estrogen and androgen do not represent separate pathways but are sequential steps in one pathway.
INTRODUCTION
In recent years, it has become clear that the concept that androgens are male hormones and estrogens are female hormones is an oversimplification. The phenotype of a human male who is homozygous for estrogen receptor ␣ (ER␣) mutation [1, 2] and of male mice in which ER␣ was inactivated [3] revealed an important role for E 2 in the skeleton, the cardiovascular system, and the reproductive tract of males. On the other hand, the parturition defects of 5␣-reductase-deficient mice [4, 5] and impaired reproductive performance and accelerated ovarian aging phenotypes of testicular feminized female (Tfm/Tfm) mice [6] revealed that androgens are important for females. 1 Supported by the Swedish Cancer Fund and by KaroBio AB. S.J. has a scholarship from Wenner Gren Foundation and Scandinavian-Japan Osakawa Foundation. The uterus is a classical 17␤-estradiol (E 2 ) target tissue, which has been used extensively to study gonadal-hormone-regulated cell proliferation. It is composed of a variety of epithelial, stromal, and smooth muscle cells, the function and hormone responsiveness of which are influenced by their position within the organ. All of the gonadal steroid hormone receptors, ER␣/estrogen receptor ␤ (ER␤), progesterone receptor (PR), and androgen receptor (AR), are expressed in this organ [7, 8] . E 2 induces epithelial cell proliferation in the uterus, and this induction is known to be indirect, i.e., the presence of ER␣ in the epithelial cells is not required. Evidence suggests that epithelial cell proliferation is mediated via stromal ER␣, which stimulates secretion of growth factors [9] . Although ER␣ is the predominant ER in the adult rodent uterus, we have previously shown that ER␤ also has a role. In the uteri of ER␤ knockout (ER␤ Ϫ/Ϫ ) mice, there is hyperresponsiveness to E 2 [8] . Progesterone is antiproliferative in the uterus, an action mediated by PR, which itself is an E 2 -inducible gene. Recent studies have shown that the induction of PR by E 2 is complex, with both ER␣ and/or ER␤ pathways involved [8, 10] .
ER␣ and ER␤ can have opposite effects on transcription of certain genes. Whether an ER will act as a transcriptional activator or repressor is influenced both by the ligand and response element on DNA with which the ER interacts. E 2 in the presence of ER␣ can activate transcription from AP-1 (activator protein-1) sites, while tamoxifen can activate AP-1 sites via ER␤ [11] . E 2 is known to induce AR in the uterus, but the roles of the two ERs in this induction remain to be defined. In the promoter region of AR, there are several AP-1 response elements [12] . Tamoxifen could be expected to decrease AR in ER␣-containing cells and increase it in ER␤-containing cells. AR is abundant in the uterus [13, 14] , and androgens have uterotrophic effects [15] . Expression of the growth factor IGF-1 as well as the multifunctional protein thioredoxin is regulated by both estrogen and androgen in the uterus [16] [17] [18] . When genes are regulated by both estrogen and androgen, it is usually assumed that the ER-and AR-dependent pathways are separate, not sequential [14, [19] [20] [21] [22] .
In this study, using immunohistochemical, Western blot, and reverse transcription-polymerase chain reaction (RT-PCR) techniques and combined treatments of E 2 with or without the antiestrogen tamoxifen and with or without the antiandrogen flutamide, we have explored the relations between ER␣/␤ and AR and their roles in controlling cell proliferation in the uterus.
MATERIALS AND METHODS

Animals and Treatments
Female Sprague-Dawley rats, 21 days old, were used. E 2 , tamoxifen, and flutamide were dissolved in Intralipid (Pharmacia & Upjohn AB, Stockholm, Sweden). There were six animals in each group, and all of them received their treatment either s.c. (for estradiol and tamoxifen) or via i.p. injections (for flutamide). The control group received vehicle. All other groups were given 10 g/kg body weight E 2 . The E 2 plus tamoxifen group was, in addition, given 60 g/kg body weight tamoxifen and the E 2 plus flutamide group 1 mg/kg body weight flutamide. Four hours after drug treatment, 100 mg/kg body weight of BrdU (5-bromo-2Ј-deoxyuridine dissolved in PBS buffer) was given to all the animals via s.c. injection. Animals were asphyxiated by CO 2 at 6, 12, or 24 h after initial treatment, and the reproductive tracts were collected. The uteri were either frozen in liquid nitrogen for RNA and protein preparation or fixed in 4% PFA (paraformaldehyde) for immunohistochemical staining.
Chemicals and Antibodies
17␤-Estradiol, tamoxifen, and flutamide were from Sigma (St. Louis, MO). 5-Bromo-2Ј-deoxyuridine (BrdU) was from Roche (Mannheim, Germany). Polyclonal antibodies against AR (N-20, rabbit) for immunohistochemical staining and cyclin A (H-432, rabbit) were from Santa Cruz (Santa Cruz, CA). AR (PA1-111A, rabbit) antibody for Western blotting was from Affinity Bioreagents (Golden, CO). Monoclonal antibody against ER␣ (6F-11) was from NovoCastra (Newcastle, U.K.). Chicken anti-human ER␤ antibody 503 was produced in this laboratory [8] and ER␤ protein 503 was provided by KaroBio (Stockholm, Sweden). Rabbit antirodent ER␤ (cat. no. 51-7900) was from Zymed (South San Francisco, CA). Peroxidase-conjugated anti-rabbit IgG was from Sigma. Biotin-conjugated goat anti-rabbit secondary antibody and VECTASTAIN ABC kits were from Vector Laboratories (Burlingame, CA). DAB (3,3Ј-diaminobenzidine) solution was from DAKO Corporation (Carpinteria, CA). Cy3-conjugated anti-chicken and anti-rabbit IgG and fluorescein isothiocyanate (FITC)-conjugated anti-rabbit and anti-mouse IgG raised in the donkey were obtained from Jackson ImmunoResearch Products (Cambridge, MA).
Detection of AR Expression by Western Blotting
With a Polytron PT3100 (Kinematica AG, Littau, Switzerland), frozen tissues were homogenized for a few seconds in a high-salt buffer (600 mM Tris-HCl, 1 mM EDTA, pH 7.4, with 1/10 w/v of homogenate). Two tablets of cocktail protease inhibitors (Boehringer Mannheim, GmbH, Germany) were added per 50 ml buffer before use. The homogenates were centrifuged at 105 000 ϫ g for 1 h at 4ЊC. Supernatants (whole cell extracts) were aliquoted and kept at Ϫ80ЊC until use. Before Western blotting, protein contents were measured by the Bio-Rad protein assay with BSA as the standard. Equal amounts of protein were loaded onto each lane of a 9% polyacrylamide gel. Western blotting was done according to the protocol described previously [23] . Antibody dilutions were 1:1000 for the anti-AR antibody (PA1-111A) and 1:3000 for the peroxidase conjugated goat anti-rabbit IgG. Signals were detected with ECL (Amersham Life Science, Buckinghamshire, U.K.).
Reverse Transcription-PCR
Tissue from each treatment group was pooled, and total RNA was isolated with a RNAWIZ kit (Ambion, Austin, TX) according the protocol provided by the company. For the RT reaction, 5 g of RNA was used from the pooled RNA of individuals of each group. The RT-PCR reactions were carried out with One-Step RT-PCR kits from Gibco BRL (cat. no. 10928-042) in a Gene Amp PCR system 2400 (Perkin-Elmer, Norwalk, CT). Primers, together with their annealing temperatures and the number of cycles, were IGF-1: forward, 5Ј-CACATCTCTTCTACCTGGCA-3Ј, reverse, 5Ј-TGAGTCTTGGGCATGTCAGT (56ЊC, 35 cycles) [24] ; Crisp: forward, 5Ј-TGTTCCTGGCTGCTGTATTG-3Ј, reverse, 5Ј-AAGACCACGATGCAG-GGTAA-3Ј (58ЊC, 35 cycles); ␤-actin: forward, 5Ј-GGGCACAGTGTGGGT-GAC-3Ј, reverse, 5Ј-CTGGCACCACACCTTCTAC-3Ј (56ЊC, 15 cycles). PCR products were resolved in a 1.5% agarose gel and stained with ethidium bromide, and DNA bands from triplicate reactions were quantified using Fluor-S MultiImager (Bio-Rad). The values of IGF-I and Crisp were normalized against ␤-actin. Results were statistically analyzed with a Student t-test, and P Ͻ 0.05 was considered as statistically significant.
Immunofluorescence Labeling of ER␣, ER␤, and AR
ER␣, ER␤, and AR were detected in tissue sections by standard immunofluorescence. Six-micrometer frozen sections were air dried for 30 min. After washing with ice-cold methanol and acetone, each for 3 min, sections were fixed for 10 min at room temperature in 4% paraformaldehyde. Antigens were retrieved by boiling in 10 mM citrate buffer in a microwave oven for 15 min. Sections were then incubated first with PBS containing 0.5% Triton X-100 for 1 h, then with 5% normal serum of the host of secondary antibodies for 30 min. For double stainings of ER␣/ ER␤ and ER␣/AR, sections were incubated sequentially with each of the two primary antibodies. Preadsorbed ER␤ antibody was prepared by incubating ER 503 IgY for 12 h at 4ЊC with ER␤ protein coupled to activated Sepharose. The ER␤ protein used was either the ER␤ 503 that was used as antigen or recombinant human ER␤ obtained from Panvera (Madison, WI).
All incubations with primary antibodies were done overnight at 4ЊC in PBS buffer containing 3% BSA and 0.3% Triton X-100. All incubations with secondary antibodies were done for 1 h at room temperature in PBS buffer containing 2% normal rat serum. After washing, the sections were mounted in Vectashield antifading medium (Vector Laboratories). The sections were examined under a Zeiss fluorescence microscope by using suitable filters for selectively detecting the fluorescence of FITC (green) and Cy3 (red). Colocalization was indicated by yellow or orange color in cells in which both FITC-and Cy3-conjugated secondary antibodies are sequestered.
For confirmation of the validity of the signals obtained with ER␤ 503 IgY, a second antibody, rabbit anti-rodent ER␤ from Zymed, was also used to detect ER␤ in the paraffin-embedded uterus. Two modes of antigen retrieval were tested with this commercial antibody. One was the citrate buffer described above and the other was the use of 0.8 M urea in place of citrate, with boiling in a microwave oven for 20 min. The avidin-biotinperoxidase method was used for staining as described previously [8] .
Immunohistochemical Evaluation of Proliferation
Six-micrometer paraffin sections were used. After antigen retrieval in citrate buffer, sections were incubated with mouse anti-BrdU IgG (1:100; PharMingen, San Diego, CA) in 3% BSA for 3 h at room temperature. For negative controls, primary antibody was replaced by 3% BSA. Slides were washed with PBS and incubated with peroxidase-conjugated secondary rabbit anti-mouse antibody (Sigma) for 1 h at room temperature. After thorough washing in PBS, sections were developed with DAB substrate (DAKO), slightly counterstained with Mayer hematoxylin, dehydrated, and mounted. Three randomly selected areas in each sample were counted for BrdU-positive cells and total cells in the luminal epithelium.
RESULTS
Regulation of AR Expression by ERs
With cytosols prepared from the uteri of immature rats, an AR band at 110 kDa was detected by Western blotting. When 50 g of protein was loaded in each lane, the AR signal was weak in samples from untreated mice, but after E 2 treatment, there was increased intensity of this AR band. Administration of tamoxifen alone also resulted in a small increase in AR over the level seen in untreated mice, which supports the partial agonist activity of tamoxifen. The E 2 -induced increase in AR was almost completely abolished by coadministration of tamoxifen together with E 2 . The 66-kDa bands on the blot were unspecific and served as a loading control (Fig. 1) .
Cellular Localization and Regulation of ER and AR
To delineate which of the two ERs is involved in the induction of AR, immunocolocalizations of ER␣, ER␤, and AR were done. In the untreated immature uterus, there was no detectable expression of AR. Upon treatment of mice with E 2 , AR was induced in stromal cells close to myometrium and in the myometrium, where it colocalized with ER␣. There was no AR expression in the epithelium.
In untreated mice, ER␣ was expressed in the luminal epithelium, in the periluminal stroma, and in the myometrium. E 2 treatment caused a decrease in the level of ER␣ in the luminal epithelium, but stromal and myometrial ER␣ remained unchanged (Fig. 2) .
In untreated mice, ER␤ was detected in both the luminal epithelium and the periluminal stroma. The ER␤ signals were completely extinguished by preadsorption of the ER␤503 antibody with ER␤ protein (Fig. 3) . Upon E 2 treatment, ER␤ signals were reduced in the epithelium but expression remained in the stromal cells surrounding the luminal epithelium. No ER␤ was detected in stroma close to myometrium and in the myometrium, regions where AR is located. Some ER␤-containing cells in the periluminal stroma also expressed ER␣ and some did not.
To test the validity of ER␤ staining in paraffin-embedded uterus, we compared a commercial antibody from Zymed, which is raised against a C-terminal peptide of ER␤, with ER␤ 503 IgY antibody that was raised against the whole ER␤ molecule. Ovaries of normal and ER␤ Ϫ/Ϫ mice were used as positive and negative controls, respectively. When citrate buffer was used for antigen retrieval, ER␤ was easily detected with the Zymed antibody in granulosa cells of the ovary in wild type mice (Fig. 4a) and rats (Fig. 4c) but not in ER␤ Ϫ/Ϫ mice (Fig. 4b ). With this antigen retrieval method, no ER␤ could be detected in the uterus (Fig. 4d) . When 0.8 M urea was used instead of citrate buffer as the antigen retrieval buffer, ER␤ was detected in most of the epithelial cells and stromal cells of the uterus of control animals (Fig.  4f) . Ovaries of ER␤ Ϫ/Ϫ mice were used as negative controls. No ER␤ signals were detected in these ovaries with either citrate (Fig. 4b) or urea as retrieval buffer (data not shown). In the positive control tissue, normal mouse ovaries, ER␤ was detected in the granulosa cells and the detection was not influenced by the retrieval procedure (Fig. 4, e and g ). With the urea antigen retrieval, it was possible to confirm, with the paraffin-embedded samples, that E 2 treatment down-regulated ER␤ in the uterine epithelium but not in the periluminal stromal cells (Fig. 4h) .
IGF-1 and Crisp in the Uterus
As judged from semiquantitative RT-PCR analysis, E 2 treatment of immature rats resulted in an increase in mRNA of two well-characterized androgen-regulated genes, IGF-1 and cysteine-rich secretory protein (Crisp) [24] , in the uterus. The E 2 induction of both genes was inhibited by tamoxifen and by flutamide (Fig. 5, A and B) .
Effects of Flutamide and Tamoxifen on the E 2 Induction of the Cell Proliferation
Animals received BrdU 4 h after hormone treatment. Uterine tissues were collected at 6, 12, and 24 h after hormone treatment. The effect of E 2 treatment on proliferation of luminal epithelial cells was evaluated immunohistochemically with specific BrdU antibody. The total BrdUpositive luminal epithelial cells were counted at each time point. As expected, in the uterus of untreated immature rats, very few luminal epithelial cells were positive. After E 2 treatment, the number of BrdU-positive cells was increased in the luminal epithelium. When administered together with E 2 , tamoxifen and flutamide each significantly inhibited E 2 -induced proliferation of the luminal epithelium (Fig. 6, A  and B) .
DISCUSSION
This study has confirmed previous findings [14, [19] [20] [21] [22] that AR is induced by E 2 and has further investigated the role of AR in E 2 -induced epithelial cellular proliferation in the immature rat uterus. We propose a pathway in which, in response to E 2 , there is sequential activation of ER␣ followed by elevation of the levels of AR, increased IGF-1 secretion, and epithelial cellular proliferation. The immunohistochemical data strongly indicate that ER␣ and not ER␤ is the estrogen receptor involved in the induction of AR. AR is not detected in the epithelial cells but is present in stromal cells, mainly myometrium, where it colocalizes with ER␣ but not with ER␤.
There are conflicting reports about whether there is ER␤ protein expression in the rodent uterus. Some laboratories have detected it and some have reported absence of immunohistochemical detection. These different experimental results may be due to differences in antibodies used and in antigen retrieval techniques employed in different laboratories [7, [25] [26] [27] [28] . In this study, we showed that the method used for antigen retrieval is a key determinant of whether or not ER␤ is detected. With a commercial antibody available from Zymed, ER␤ was detected in both the luminal epithelium and the periluminal stroma when the antigen retrieval buffer was 0.8 M urea but not when citrate was used. With the 503 IgY antibody in frozen sections, the pattern of distribution of ER␤ was similar to what is seen in urea retrieved sections with the Zymed antibody, but the 503 IgY did not give satisfactory results with paraffin-embedded sections whether citrate or urea was used for retrieval. In the granulosa cells of the ovary, ER␤ could be detected with either retrieval method. The need for a harsher retrieval method in sections from the uterus could be due to the lower levels of ER␤ in the uterus or might indicate that ER␤ in the uterus exists in a receptor complex that is different from that in the granulosa cells.
Since the antiandrogen flutamide can block E 2 induction of IGF-1 as well as Crisp and luminal epithelial proliferation as measured by BrdU labeling, AR most likely participates in E 2 -induced luminal epithelial proliferation in the rat uterus. It has been shown that the E 2 -induced proliferation of uterine epithelial cells is controlled by growth factors from the stroma and that it is the ER␣ in the stroma but not in the epithelium that is responsible [9] . IGF-1 is one of the major growth factors involved in stimulation of cellular proliferation in the uterus [29] and has been shown to be regulated by both E 2 and androgen in this tissue [30, 31] . The major IGF-1-producing compartment of the uterus is the myometrium [32] , where both ER␣ and AR are induced by estradiol. We found in this study that most of the induction of IGF-1 by E 2 is mediated by AR because the E 2 -induced expression of IGF-1 mRNA was reduced from 3-fold to 1.3-fold by flutamide. The residual induction of IGF-1 mRNA expression in the presence of flutamide may reflect the involvement of PR in mediating estradiol-induced IGF-1 expression [33] .
The effect of flutamide on estrogen-induced rat uterine growth was studied decades ago [34, 35] . In these studies, no effects of flutamide were found on the estradiol- induced FIG. 4 . Comparison of different antigen retrieval methods in detecting ER␤ in the uterus with commercial antibody. Using citrate buffer for antigen retrieval with ovaries of wild-type mouse (a), ER␤ Ϫ/Ϫ mouse (b), and normal rat (c), ER␤ can be easily detected in granulosa cells (arrows) but not in the uterus (d). With 0.8 M urea as retrieval buffer, granulosa cells in the rat ovary (e) are still positive, and in the control mouse uterus (f), positive signals are seen in most of luminal epithelial cells (arrows) and stroma cells (arrow heads). E 2 treatment had no effect on the expression of ER␤ in granulosa cells (g). In the uterus, E 2 down-regulates ER␤ in the luminal epithelium and myometrium (arrows) but had no effect on ER␤ in the stromal cells surrounding the luminal epithelium (arrow heads) (h). Bars ϭ 50 m.
uterine weight change. It is known that the uterine weight gain induced by estradiol is mostly due to the increased water imbibition and protein secretion [36] , which do not necessarily indicate proliferation. With BrdU labeling in this study, we found that the estradiol-induced uterine luminal epithelial cell proliferation was inhibited by both tamoxifen and flutamide at three time points, 6, 12, and 24 h.
Crisp is transcriptionally regulated by androgens in several tissues in the male urogenital tract [37] , in the lacrimal gland of both male and female mice [38] , and in human and mouse glandular tissues [39] . The presence of Crisp in the uterus is a novel finding. It was found, by protein sequencing, to be one of several proteins that were overexpressed in the uterine secretion fluid of E 2 -treated ER␤ Ϫ/Ϫ mice (unpublished data). Its regulation in the uterus by E 2 , and inhibition of this E 2 induction by an antiestrogen and an antiandrogen provides further support for the existence of an ER␣-AR sequential pathway.
Before puberty, the ovary secrets androgens. Just before first ovulation, the ovary turns from an androgen-producing tissue to an estrogen-producing tissue [40] . The ovarian androgens produced before puberty are most likely the source of the ligands for AR in the E 2 -treated uterus shown in this study.
ER␤ is mostly expressed in the stromal cells surrounding the lumen, a population of cells lacking AR expression. Some of these ER␤-containing cells do not express ER␣. In a previous study, we found that, in ER␤ Ϫ/Ϫ mice, there is increased IGF-I expression and exaggerated cellular proliferation in response to E 2 in the immature mouse uterus [8] . ER␣ and ER␤ are known to have opposite effects on expression of genes that are regulated by the AP-1 site [11] . AR is a candidate gene in this category since there are several AP-1 sites in the promoter region of the AR gene [12] . In the presence of tamoxifen, transcription of genes, which is regulated by ER␤ via AP-1 sites, should be increased. We speculate that AR is such a gene and that tamoxifen-induced proliferation in the uterus is a result of this ER␤-AP-1 pathway. This interpretation remains speculative because tamoxifen can also act as a partial agonist with ER␣.
Upon E 2 treatment, both ER␣ and ER␤ were down-reg-ulated in the luminal epithelial cells, but in the periluminal stromal cells, ER␤ was not down-regulated. Because these are the cells that undergo decidualization during implantation of the embryo and because E 2 is essential for this process, ER␤ may play a role in implantation [27] . In many systems where E 2 and testosterone have similar effects [41, 42] , the reason for the apparent dual regulation is the conversion of testosterone to estrogen by local aromatase. In such systems, antiandrogens do not block the effects of androgen since the response is mediated by ER. In other systems, nonaromatizable androgens can mimic the effects of E 2 [43] [44] [45] . In these systems, both ER and AR participate. In such situations, the E 2 response is blocked by antiestrogens and the androgen response by antiandrogens. In the present study, we have shown that the proliferative response of the uterus to E 2 can be blocked by both an antiestrogen and an antiandrogen. This suggests that ER and AR constitute two sequential steps in a single pathway, where ER regulates AR expression and AR amplifies the E 2 signaling. Because ER␣ but not ER␤ colocalizes with AR, this pathway is composed of ER␣ and AR. There is much evidence that E 2 -induced proliferation in the epithelium is indirect and requires ER␣ in the stroma, not in the epithelium. We suggest that proliferation is due to IGF-1 released from the stroma through the action of AR. In those regions where ER␣, AR, and IGF-1 are colocalized, ER␣ induces AR and AR increases IGF-1 levels.
There is much discussion today about whether or not androgens should be included along with estrogen and progesterone in hormone replacement therapy (HRT) of postmenopausal women [46] . There appear to be beneficial effects of androgen on maintenance of bone, improvement of mood, and reversal of sexual dysfunction [47] . The present data suggests that androgens can also stimulate proliferation of the uterine epithelium. Whether or not inclusion of androgen in HRT increases the risk for uterine proliferation cannot be evaluated from the present studies. However, it is clear that, for optimal HRT, the roles of all four gonadal hormone receptors should be considered.
